IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients

Philippe Metellus (1) , Carole Colin (2) , David Taieb (3) , Eric Guedj (3) , Isabelle Nanni-Metellus (4) , Andre Maues de Paula (5) , Cécile Colavolpe (5) , Stephane Fuentes (1) , Henry Dufour (1) , Marylin Barrie (6) , Olivier Chinot (6, 2) , L’houcine Ouafik (2, 4) , Dominique Figarella-Branger (2, 5)

1 Département de Neurochirurgie [CHU Timone]
2 CRO2 - Centre de Recherches en Oncologie biologique et Oncopharmacologie
3 Service Central de Biophysique et de Médecine Nucléaire
4 Laboratoire de Transfert d'Oncologie Biologique [Hôpital Nord - APHM]
5 Service d'Anatomie Pathologique et de Neuropathologie
6 Département de neurooncologie

Domains: Life Sciences [q-bio]; Cancer

Philippe Metellus, Carole Colin, David Taieb, Eric Guedj, Isabelle Nanni-Metellus, et al.. IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. Journal of Neuro-Oncology, 2011, 105 (3), pp.591 - 600. ⟨10.1007/s11060-011-0625-2⟩. ⟨hal-01827536⟩